ES2196361T3 - Combinaciones terapeuticas de antagonistas de rar y agonistas de rxr. - Google Patents

Combinaciones terapeuticas de antagonistas de rar y agonistas de rxr.

Info

Publication number
ES2196361T3
ES2196361T3 ES97939631T ES97939631T ES2196361T3 ES 2196361 T3 ES2196361 T3 ES 2196361T3 ES 97939631 T ES97939631 T ES 97939631T ES 97939631 T ES97939631 T ES 97939631T ES 2196361 T3 ES2196361 T3 ES 2196361T3
Authority
ES
Spain
Prior art keywords
rar
therapeutic combinations
rar antagonists
rxr agonists
rxr agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97939631T
Other languages
English (en)
Inventor
Pierre Chambon
Hinrich Gronemeyer
Peter R Dept Reczek
Jacek Dept Ostrowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Strasbourg
Bristol Myers Squibb Co
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Strasbourg
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Strasbourg, Bristol Myers Squibb Co filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of ES2196361T3 publication Critical patent/ES2196361T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Quinoline Compounds (AREA)

Abstract

LA INVENCION SUMINISTRA COMPOSICIONES Y PROCEDIMIENTOS PARA TRATAR UN ANIMAL, PREFERIBLEMENTE UN HUMANO, QUE SUFRA O ESTE PREDISPUESTO A UNA ENFERMEDAD FISICA MEDIANTE LA ADMINISTRACION DE UNA CANTIDAD EFECTIVA DE UNA COMPOSICION QUE COMPRENDE AL MENOS UN ANTAGONISTA DE RAR PREFERIBLEMENTE UN ANTAGONISTA DE RAR AL , Y AL MENOS UN AGONISTA DE RXR. LA COMBINACION DE UN AGONISTA DE RXR, QUE NO TIENE EFECTOS TERAPEUTICOS POR SI SOLO, CON UN ANTAGONISTA DE RAR PERMITE EL USO DE DOSIS DEL ANTAGONISTA DE RAR MENORES DE LO QUE PREVIAMENTE SE PENSABA; ESTA APROXIMACION OBVIA MUCHOS EFECTOS COLATERALES FISIOLOGICOS NO DESEABLES DEL TRATAMIENTO CON ANTAGONISTAS DE RAR.
ES97939631T 1996-08-28 1997-08-28 Combinaciones terapeuticas de antagonistas de rar y agonistas de rxr. Expired - Lifetime ES2196361T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2477296P 1996-08-28 1996-08-28

Publications (1)

Publication Number Publication Date
ES2196361T3 true ES2196361T3 (es) 2003-12-16

Family

ID=21822317

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97939631T Expired - Lifetime ES2196361T3 (es) 1996-08-28 1997-08-28 Combinaciones terapeuticas de antagonistas de rar y agonistas de rxr.

Country Status (11)

Country Link
US (2) US6130230A (es)
EP (1) EP0928200B1 (es)
JP (1) JP2001500486A (es)
AT (1) ATE236654T1 (es)
AU (1) AU731060B2 (es)
CA (1) CA2263817A1 (es)
DE (1) DE69720745T2 (es)
ES (1) ES2196361T3 (es)
IL (1) IL128723A0 (es)
NO (1) NO990912L (es)
WO (1) WO1998008546A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018885A1 (en) 1998-09-29 2000-04-06 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
CA2254429A1 (en) * 1998-11-19 2000-05-19 Tully Michael Underhill Compositions for promoting chondrogenesis
AU4228000A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
US6436993B1 (en) * 1999-07-13 2002-08-20 The Salk Institute For Biological Studies Use of RAR antagonists as modulators of hormone mediated processes
CA2402413A1 (en) * 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis
AU4866201A (en) * 2000-04-13 2001-10-30 Pierre Chambon Compositions and methods for use in modulating immune system function
WO2001092578A2 (en) * 2000-05-26 2001-12-06 Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by retinoids
US6713515B2 (en) 2000-09-13 2004-03-30 Bristol Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
EP1478384A2 (en) * 2001-06-11 2004-11-24 Ludwig Institute For Cancer Research Method for increasing the survival of dopamine secreting cells
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en) 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US20040097587A1 (en) * 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
JP4473491B2 (ja) * 2002-05-28 2010-06-02 株式会社資生堂 毛穴縮小剤
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US20050112123A1 (en) * 2003-10-06 2005-05-26 Vaughan Michael R. Methods of treating proteinuria
GB2411115A (en) * 2004-02-19 2005-08-24 Medical Res Council Retinoic acid antagonists for the treatment of oesophageal disorders
WO2006030442A2 (en) 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
EP2181710A1 (en) * 2008-10-28 2010-05-05 Phenex Pharmaceuticals AG Ligands for modulation of orphan receptor-gamma (NR1F3) activity
EP2329817A1 (en) * 2009-09-04 2011-06-08 Ernst-Moritz-Arndt-Universität Greifswald Retinoic acid receptor antagonists, miR-10a inhibitors and inhibitors of HOXB1 or HOXB3 repressors for treating pancreatic cancer
AU2012272642B2 (en) * 2011-06-24 2017-09-07 Gri Bio, Inc. Prevention and treatment of inflammatory conditions
HK1202581A1 (en) 2012-02-13 2015-10-02 Gamida-Cell Ltd. Mesenchymal stem cells conditioned medium and methods of generating and using the same
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
WO2015026990A2 (en) 2013-08-20 2015-02-26 University Of Washington Through Its Center For Commercialization Novel and specific inhibitors of cytochrome p450 26 retinoic acid hydrolase
EP3380086B1 (en) 2015-11-25 2021-10-13 IO Therapeutics, Inc. Cyp26-resistant rar-alpha selective agonists in the treatment of cancer
WO2017214575A1 (en) * 2016-06-10 2017-12-14 Io Therapeutics, Inc. Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
WO2019014468A1 (en) 2017-07-13 2019-01-17 Io Therapeutics, Inc. RECEPTOR SUBTYPE AND RETINOID COMPOUNDS AND SELECTIVE REXINOIDS OF A FUNCTION IN COMBINATION WITH IMMUNE MODULATORS FOR ANTICANCER IMMUNOTHERAPY
US10363272B2 (en) 2017-08-31 2019-07-30 Io Therapeutics, Inc. RAR selective agonists in combination with immune modulators for cancer immunotherapy
US12115140B2 (en) * 2020-07-31 2024-10-15 The Trustees Of Columbia University In The City Of New York Method of treating adenoid cystic carcinoma

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2100582A1 (en) 1991-03-18 1992-09-19 David J. Mangelsdorf Response element compositions and assays employing same
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
EP0659045A4 (en) * 1993-05-18 1997-02-26 Inst Nat Sante Rech Med MOUSE GENETICALLY GENERATED AND COMPRISING MODIFICATIONS IN GENES ENCODING RETINOIC ACID RECEPTOR PROTEINS.
US5702914A (en) * 1994-12-21 1997-12-30 The Salk Institute For Biological Studies Use of reporter genes for retinoid receptor screening assays having novel retinoid-associated response elements
US5747661A (en) * 1995-01-13 1998-05-05 Howard Hughes Medical Institute Retinoid-inducible response elements
AU4530496A (en) 1995-01-13 1996-07-31 Salk Institute For Biological Studies, The Allosteric control of nuclear hormone receptors
US5559248A (en) * 1995-04-05 1996-09-24 Bristol-Myers Squibb Co. Retinoid-like heterocycles
US6025388A (en) * 1995-04-26 2000-02-15 Allergan Sales, Inc. Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids
US5906920A (en) 1995-08-29 1999-05-25 The Salk Institute For Biological Studies Methods for the detection of ligands for retinoid X receptors
CA2276288A1 (en) 1996-12-31 1998-07-09 Laszlo Nagy Treatment of disease states which result from neoplastic cell proliferation using ppar-gamma activators and compositions useful therefor
AU5727998A (en) 1996-12-31 1998-07-31 Salk Institute For Biological Studies, The Treatment of liposarcomas using a combination of thiazolidinediones and retinoidx receptor selective agonists
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds

Also Published As

Publication number Publication date
NO990912L (no) 1999-04-27
DE69720745D1 (de) 2003-05-15
WO1998008546A2 (en) 1998-03-05
EP0928200A2 (en) 1999-07-14
DE69720745T2 (de) 2004-02-26
AU731060B2 (en) 2001-03-22
WO1998008546A8 (en) 2001-04-19
AU4167497A (en) 1998-03-19
NO990912D0 (no) 1999-02-25
JP2001500486A (ja) 2001-01-16
CA2263817A1 (en) 1998-03-05
EP0928200B1 (en) 2003-04-09
IL128723A0 (en) 2000-01-31
ATE236654T1 (de) 2003-04-15
US6130230A (en) 2000-10-10
WO1998008546A3 (en) 1998-04-23
US6653322B1 (en) 2003-11-25

Similar Documents

Publication Publication Date Title
ES2196361T3 (es) Combinaciones terapeuticas de antagonistas de rar y agonistas de rxr.
DK0586621T3 (da) Linsidomin til behandling af erektile dysfunktioner
DE60235775D1 (de) Intraluminale Vorrichtung mit einer therapeutisches-mittel enthaltenden Beschichtung
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
ES2194050T3 (es) Uso de bisfosfonatos para inhibir la resorcion osea tras la implantacion de una protesis osea.
BR0115392A (pt) Método para o tratamento de uma doença sensìvel a interferona em um animal de sangue quente, método para individualizar as dosagens de uma interferona no tratamento, método para a fabricação de um dispositivo de liberação de efeito terapêutico de longa duração de uma droga ao longo de um perìodo de tempo, e conjunto útil para a ministração de uma quantidade relativamente constante de uma droga
AR008444A1 (es) Empleo de antagonistas de leptina para el tratamiento de la resistencia a la insulina en diabetes del tipo ii
CU23226B7 (es) COMPOSICIONES ANALGéSICAS QUE COMPRENDEN COMPUESTOS ANTI-EPILéPTICOS Y ANTINFLAMATORIOS NO ESTEROIDEOS
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
ES2156839T1 (es) Medicamento que contiene alginato e implante para tratar la fibrosis.
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
ES2173294T3 (es) Nuevo uso medico.
AR036970A1 (es) Composicion farmaceutica androgenica y metodo para el tratamiento de la depresion
MX9300558A (es) Nueva sulfonilurea, procedimiento para su preparacion y formulado farmaceutico que la contiene.
UY24063A1 (es) Empleo de concentrados con contenido de factor von willebrand (vwf) como terapia de combinacion en la terapia con antitromboticos y fibrinoliticos
ATE297732T1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
HUP0401634A2 (hu) LHRH-antagonisták használata kasztrációt nem okozó dózisokban a T-sejtes immunitás javítására és gyógyszerkészítmények előállítására
ES2185310T3 (es) Agente antivirico herbario.
DE60008590D1 (de) Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
ES2211996T3 (es) Agentes de union a receptores de acido hialuronico y su uso para el tratamiento de tumores o de reestenosis.
ATE277639T1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
DE60008589D1 (de) Zusammensetzungen von adenosin a1 agonisten mit 5ht1 agonisten